Infex Therapeutics

News

UK biotech Infex is in hot pursuit of Insmed's Brinsupri, the only approved therapy for non-CF bronchiectasis, with its quarterly-dosed antibody.

News

Insmed is working with a bronchiectasis patient organisation on a real-world trial of Brinsupri, the first FDA-approved drug for the lung disorder.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.